News Releases

Month Year

Jun 13, 2018

RegeneRx Holds Annual Meeting

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), today held its 2018 Annual Meeting. Seventy-eight of the Company's stockholders voted on four proposals. Each...
May 29, 2018

RegeneRx Corrects Annual Meeting Date to Wednesday, June 13, 2018

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), today is correcting a misprinted annual meeting date in the Company's proxy materials that were sent to its...
May 2, 2018

ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eye Syndrome in a Mouse Model at ARVO

ReGenTree, LLC (the "Company"), a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals (OTCQB: RGRX), announced today that the Company presented results of a comparison study of RGN-259...
Apr 25, 2018

GtreeBNT Discloses Preliminary Observations from Seventeen NK Patients Treated with RGN-259 Eye Drops

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today is informing...
Apr 9, 2018

RegeneRx Announces Outcome of FDA Discussions for Development of RGN-259 for Dry Eye Syndrome

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced the...
Mar 14, 2018

RegeneRx Receives Notice of Allowance of U.S. Patent for Treatment of Corneal Wounds

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Mar 12, 2018

RegeneRx Receives "Decision to Grant" European Patent For Treatment of Peripheral Neuropathy

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Mar 2, 2018

RegeneRx Secures $1 Million in Funding

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Feb 22, 2018

Key U.S. Dry Eye Patent Issued to RegeneRx

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Feb 14, 2018

RegeneRx Receives Canadian Patent for Treating Neurological Injury and Damage

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Dec 7, 2017

RegeneRx Releases Annual Letter to Shareholders

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Nov 16, 2017

Tβ4's Role in Treatment of Eye Diseases Showcased at 5th International Thymosin Symposium

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Oct 31, 2017

RegeneRx JV Announces Results of ARISE-2 Dry Eye Trial

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced the...
Sep 13, 2017

RegeneRx Receives Notice of Allowance for Key Dry Eye Patent in U.S.

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Aug 31, 2017

RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia

Proceeds will Fund Operations Beyond Receipt of Phase 3 Dry Eye Trial Data

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Aug 30, 2017

RegeneRx Announces Participation At The 19th Annual Rodman & Renshaw Global Investment Conference In New York September 10-12, 2017

Presenting on Monday, September 11 at 11:40 AM ET

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced it...
Aug 14, 2017

RegeneRx Collaborators Receive Notice of 'Intent to Grant' EU Patent for the Treatment of Peripheral Neuropathy

Research Conducted Under Material Transfer Agreement Provides Potential Large Therapeutic Market Target for RGN-352 in the U.S. and EU

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Jul 27, 2017

RegeneRx Updates on RGN-259 Phase 3 Dry Eye Trial

Last Patient, Last Visit Completed on July 20th

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Jun 13, 2017

RegeneRx Collaborators Receive Notice of Allowance of U.S. Patent for the Treatment of Peripheral Neuropathy

Research Conducted Under Material Transfer Agreement Provides Potential Therapeutic Target for RGN-352

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
May 9, 2017

RegeneRx JV Presents Results of Phase 2b/3 (ARISE-1) Dry Eye Trial at ARVO 2017

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced that its...
Mar 13, 2017

RegeneRx Releases Annual Letter to Shareholders

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Feb 27, 2017

RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S.

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Jan 9, 2017

RegeneRx Receives Notice of Acceptance for Patent in Australia For Treatment of Neural Injury with Thymosin Beta 4.

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Dec 16, 2016

RegeneRx Receives Notice of Intent to Grant Patent in EU for Treating Neural Injury with Thymosin Beta 4

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Nov 30, 2016

RegeneRx to Present at 9th Annual LD Micro Investor Conference

Presentation on Tuesday, December 6, 2016 at 3:30 pm PT

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...

Show per page